Letters of Intent due 2.1 2020. Research focus is highly translational. Topics must fall within any of the following research priorities:
- Projects that are likely to lead to clinical treatment trials within 5 years. This includes the discovery and/or testing of candidate treatment compounds in cell based or animal models of HGPS. Only proposals that test compounds in a progerin producing animal or cell model will normally be considered. Analyses in non progerin-producing models are acceptable, but only as a comparison to progerin producing models and with strong justification.
- Development of gene- and cell-based therapies to treat Progeria
- Assessment of natural history of disease that may be important to developing outcome measures in treatment trials (preclinical or clinical)
Letter of Intent: A letter of intent is required and must be approved before a full application will be considered.
Phase I Proposals: Awards are typically for 1-2 years in the range of USD $75,000 per year. PRF will conduct a thorough cost analysis for each project during evaluations of submissions.
Required Qualifications: Principal investigators must hold a faculty appointment or equivalent. Awards will be granted only to applicants affiliated with institutions with 501(c)3 tax-exempt status, or the equivalent for foreign institutions.
Project Facilitation for Grant Awards: Grant advisor, usually a member of the PRF Medical Research Committee, will be assigned to each funded project. The grant advisor will meet (via phone or teleconference) with the grantee at strategic times throughout the project period. Progress report will be submitted every 6 months (grant months 6, 12, 18, and a final report within 30 days of the end date of the grant)
Phase II Proposals: Phase I investigators may be invited to submit a follow-up grant proposal, so that highly promising research projects can continue to benefit the field of Progeria. These proposals are generally by invitation only, and will be reviewed on the regularly scheduled grant review meeting dates.
Call Notice [PDF]